Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.
Sensei Biotherapeutics (Nasdaq: SNSE), una societ脿 biotecnologica in fase clinica specializzata in terapie oncologiche di nuova generazione, ha annunciato la sua partecipazione a un prossimo evento del settore. John Celebi, Presidente e CEO, sar脿 un relatore nel dibattito su Nuove Approcci alla Radioterapia e alla Terapia Mirata durante la Conferenza Virtuale Canaccord Genuity Horizons in Oncology. Il panel 猫 programmato per luned矛 7 aprile alle 14:00 ET.
Sensei Biotherapeutics (Nasdaq: SNSE), una empresa biotecnol贸gica en etapa cl铆nica especializada en terapias oncol贸gicas de nueva generaci贸n, ha anunciado su participaci贸n en un pr贸ximo evento de la industria. John Celebi, Presidente y CEO, ser谩 panelista en la discusi贸n sobre Nuevos Enfoques en Radioterapia y Terapia Dirigida en la Conferencia Virtual Canaccord Genuity Horizons in Oncology. El panel est谩 programado para el lunes 7 de abril a las 2:00 p.m. ET.
靹检劯鞚� 靸濍獏瓿淀暀 (Nasdaq: SNSE), 彀劯雽� 鞎� 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓臧� 雼り皜鞓る姅 靷办梾 頄夓偓鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 臁� 靺�霠堧箘, 靷灔 瓴� CEO臧� 旌愲剤旖旊摐 鞝滊壌鞚错嫲 順鸽澕鞚挫鞀� 鞚� 鞓綔搿滌 臧�靸� 須岇潣鞐愳劀 靸堧鞖� 氚╈偓靹� 旃橂 氚� 響滌爜 旃橂 鞝戧芳氩曥棎 雽�頃� 韺剱毽姢韸鸽 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 韺剱鞚� 4鞗� 7鞚� 鞗旍殧鞚� 鞓ろ泟 2鞁滌棎 鞓堨爼霅橃柎 鞛堨姷雼堧嫟. ET.
Sensei Biotherapeutics (Nasdaq: SNSE), une entreprise de biotechnologie en phase clinique sp茅cialis茅e dans les th茅rapies anticanc茅reuses de nouvelle g茅n茅ration, a annonc茅 sa participation 脿 un prochain 茅v茅nement de l'industrie. John Celebi, Pr茅sident et CEO, sera pan茅liste lors de la discussion sur les Nouvelles Approches en Radioth茅rapie et Th茅rapie Cibl茅e lors de la Conf茅rence Virtuelle Canaccord Genuity Horizons in Oncology. Le panel est pr茅vu pour le lundi 7 avril 脿 14h00 ET.
Sensei Biotherapeutics (Nasdaq: SNSE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien der n盲chsten Generation gegen Krebs spezialisiert hat, hat seine Teilnahme an einer bevorstehenden Branchenveranstaltung bekannt gegeben. John Celebi, Pr盲sident und CEO, wird als Podiumsteilnehmer an der Diskussion 眉ber Neue Ans盲tze in der Strahlentherapie und gezielten Therapie auf der Canaccord Genuity Horizons in Oncology Virtuellen Konferenz teilnehmen. Das Panel ist f眉r Montag, den 7. April um 14:00 Uhr ET angesetzt.
- None.
- None.
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer,听will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.
About Sensei Biotherapeutics听
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb鈩� (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei鈥檚 lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit听, and follow the company on X @SenseiBio and听.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
Media Contact:
Joyce Allaire
LifeSci Advisors
FAQ
When is Sensei Biotherapeutics (SNSE) presenting at the Canaccord Genuity Oncology Conference?
What panel will SNSE CEO John Celebi participate in at the Canaccord conference?
What is Sensei Biotherapeutics' (SNSE) current development focus?
What is Sensei Biotherapeutics' (SNSE) current stage of development?
